K.B. Kotade*1, P.Kadbhane1, S.B Somwanshi2, K.B.Dhamak3
1Department of Pharmacology, P.R.E.S.’s, College of Pharmacy (For Women), Chincholi, Nashik-422 102.
2Department of Pharmaceutics, P.R.E.S.’s, College of Pharmacy (For Women), Chincholi, Nashik-422 102.
3Department of Pharmaceutical Chemistry, P.R.E.S.’s, College of Pharmacy (For Women), Chincholi, Nashik-422 102
A B S T R A C T
The term myeloproliferative disorder (MPD) was first introduced by Dr William. Myeloproliferative disorder is the general name given to a group of conditions where there is an overgrowth of cells in the bone marrow, often leading to increased number of cells in the blood. Myeloproliferative disorders are described according to the blood cell which is most affected. There are four types of myeloproliferative disorder that together represent around 95% of all cases. Polycythemia Vera (PV), Essential thrombocythemia (ET), Primary or idiopathic myelofibrosis (PMF), Chronic myelogenous leukemia (CML).Uncommon types of myeloproliferative disorder together make up about 5% of cases are chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), Mastocytosis. MPD can be diagnosed by using a combination of laboratory tests and a physical examination. The treatment or combination of treatment chosen will depend on several factor including the duration and severity of disorder, whether or not you have a history of blood clots, age and general health. A mutation of a gene known as jenus kinase (JAK 2) is found in large proportion of people with myeloproliferative disorder. The discovery of mutation in JAK2 gene is important because it has significant impact on the way myeloproliferative disorder are diagnosed and may be important for treatment in the future.
Keywords: Bone marrow, Jenus kinase, Leukemia, Mutation, Myeloproliferative disorder (MPD).